Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**XMMME-001-DTPA 111 Indium** is an experimental indium-111 radiolabeled murine antimelanoma monoclonal antibody developed for diagnostic imaging of systemic and nodal melanoma metastases. The XMMME-001 antibody component recognizes high-molecular-weight melanoma-associated antigens, while the DTPA chelator complexes indium-111, enabling gamma-camera and single-photon emission computed tomography detection of antibody-localized tumor sites. It is a diagnostic radioimmunoconjugate rather than the related ricin A-chain immunotoxin XMMME-001-RTA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on XMMME-001-DTPA 111 Indium.